<DOC>
	<DOCNO>NCT01202890</DOCNO>
	<brief_summary>This study test feasibility combine 3 drug , Revlimid Doxil Bevacizumab , gather preliminary data potential activity combination patient platinum resistant/refractory ovarian cancer .</brief_summary>
	<brief_title>Study Revlimid With Doxil Avastin Patients With Platinum Resistant Ovarian Cancer</brief_title>
	<detailed_description>The combination Doxil Avastin several aspect interest ovarian cancer treatment : 1 ) independent single-agent activity , 2 ) enhance localization Doxil possible tumoral interstitial pressure via increase half-life ( liposomal egress diminish ) decrease [ 42 ] , 3 ) improve Doxil distribution , 4 ) likely favorable toxicity profile since Doxil 's common problematic toxicity skin ( palmar-plantar erythrodysesthesia PPE ) . Lenalidomide also antiangiogenic property , different mechanism action Avastin . Given preliminary result effect combination Doxil Avastin , show increase progression-free survival , interested use new thalidomide analog maximize angiogenic inhibition . This study test feasibility combine 3 drug , gather preliminary data potential activity combination patient platinum resistant/refractory ovarian cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>EOC patient must platinum resistant/refractory ( see 1.1 definition ) consider attend physician capable treat study accord GCP . Measurable disease RECIST criterion evaluable disease GCIC criteria No prior anthracycline lenalidomide use , unless dose receive equal less one cycle patient progress treatment . Subjects must calculate creatinine clearance &gt; 60ml/min CockcroftGault formula escalation phase . Subjects must calculate creatinine clearance ≥ 30ml/min CockcroftGault formula expansion phase . See section , `` Dosing Regimen '' , regard lenalidomide dose adjustment calculate creatinine clearance &gt; 30ml/min &lt; 60ml/min . Understand voluntarily sign informed consent form . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control . No contraindication anticoagulation Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . Concurrent use anticancer agent treatment . Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine eligible . History thromboembolic event within last 3 month Known hypersensitivity component Avastin</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>lenalidomide</keyword>
	<keyword>revlimid</keyword>
	<keyword>liposomal doxorubicin</keyword>
	<keyword>doxil</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>avastin</keyword>
	<keyword>platinum resistant ovarian cancer</keyword>
	<keyword>ovarian cancer</keyword>
</DOC>